MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Shuomeng Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin 150…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Harbin Medical University, Postdoctoral Scientific Research Development Fund of Heilongjiang Province, Ministry of Education of the People's Republic of China.
Abstract (Originalsprache)
BACKGROUND: Cisplatin-based chemotherapy has been widely used in the treatment of lung adenocarcinoma (LUAD). However, the development of cisplatin resistance becomes a major obstacle impeding the curative effect. It remains necessary to uncover the molecular mechanism of cisplatin resistance. METHODS: Based on the CCLE database, lung cancer cell lines were divided into cisplatin-resistant and cisplatin-sensitive groups. The differentially expressed miRNAs were filtered and further identified by survival prognosis analysis. After transfection with miR-375 inhibitor or mimic, cell cytotoxicity assay, flow cytometry and western blot were conducted to validate the role of miR-375. The transcription factor (TF)-miRNA network was constructed based on TransmiR. The target genes of miR-375 were predicted by Starbase and further verified by RT-qPCR and immunohistochemistry results in the Human Protein Atlas. Functional enrichment analysis was performed with GO terms and KEGG. RESULTS: In this study, miR-375 showed the ability to promote cisplatin sensitivity and apoptosis of LUAD. Genes correlated with miR-375 in LUAD were analyzed and ABCC8 showed the strongest positive correlation. Moreover, transcription factors that regulate miR-375 expression were predicted. MBNL1, PTPN3, PRKD1 and RPN1 were identified as the target genes of miR-375. Enrichment analysis demonstrated that miR-375-related genes associated with promoting cell proliferation and anti-apoptosis were involved in the MAPK signaling pathway. CONCLUSION: Overall, this study provides new insights into the role of miR-375 in the cisplatin sensitivity of LUAD. Our present findings may serve as a theoretical basis for new therapeutic strategies and predictive models of cisplatin resistance in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin 150081, China; Laboratory of Medical Genetics, Harbin Medical University,…
- Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Förderung
- Harbin Medical University
- Postdoctoral Scientific Research Development Fund of Heilongjiang Province
- Ministry of Education of the People's Republic of China
Zitieren
APA
Du, S., Qu, H., Zhang, Y., Zhu, S., Wang, Y., Zhang, S., Wang, Z., Yang, Q., Fu, S., & Dong, K. (2023). MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154765
Vancouver
Du S, Qu H, Zhang Y, Zhu S, Wang Y, Zhang S, et al. MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154765
BibTeX
@article{Du2023,
author = {Du, Shuomeng and Qu, Han and Zhang, Ying and Zhu, Shihao and Wang, Yang and Zhang, Shuopeng and Wang, Zhao and Yang, Qian and Fu, Songbin and Dong, Kexian},
title = {MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154765}
}
EUVIMED